ALC Stock Chart & Stats
$81.32
-$0.68(-0.81%)
At close: 4:00 PM EST
$81.32
-$0.68(-0.81%)
Day’s Range― - ―
52-Week Range$61.84 - $92.55
Previous Close$87.56
Volume942.02K
Average Volume (3M)1.94M
Market Cap
$34.88B
Enterprise Value$31.95K
Total Cash (Recent Filing)$1.66B
Total Debt (Recent Filing)$5.25B
Price to Earnings (P/E)42.2
Beta0.68
Next Earnings
Aug 10, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)1.65
Shares Outstanding499,700,000
10 Day Avg. Volume2,398,562
30 Day Avg. Volume1,943,955
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$86.93Price Target Upside6.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)3.39
Revenue Forecast (FY)$10.86B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a sizable equity base provide durable financial flexibility to fund R&D, capital equipment placements and strategic M&A while supporting a multi-year share repurchase program. This containment of financial risk helps the firm weather cyclical procedure softness without forcing asset sales.
Recurring Consumables & Installed BaseAlcon's business model pairs capital equipment placements with recurring consumables and lenses, creating predictable, repeatable revenue streams. Installed-base-driven consumable demand and wide distribution across surgical and vision channels support steady cash generation and resilience to single-product shocks.
Product Innovation & Share GainsRecent launches (Unity platform, PanOptix Pro, Tryptyr) are translating into equipment acceleration, share gains and refill adoption, demonstrating sustainable competitive advantage from innovation. Continued successful new-product adoption should drive installed-base growth and higher-margin follow-on sales over multiple years.
Bears Say
Recent Profitability & FCF SoftnessTrailing‑twelve‑month net income and free cash flow have meaningfully softened versus prior year, and cash conversion sits below 1x. If this earnings-to-cash translation weakness persists, it could constrain reinvestment, slow equipment placement cadence, and reduce flexibility for buybacks or dividend growth.
Tariff-Related Margin PressureIncremental and unpredictable import tariffs have compressed gross margins and introduced a structural cost overhang. While assumed tariff rates were revised lower, ongoing trade policy volatility can erode margin sustainability and free cash flow, forcing higher prices or margin sacrifice over the medium term.
Geographic & Procedure CyclicalityRevenue depends on elective procedure volumes and geographic performance; weakness in China and softer cataract markets create downside to implantables and consumables. Geographic concentration and procedure cyclicality can cause multi‑quarter revenue swings, limiting consistency of growth absent broader procedure recovery.
Alcon News
ALC FAQ
What was Alcon’s price range in the past 12 months?
Alcon lowest stock price was $61.84 and its highest was $92.55 in the past 12 months.
What is Alcon’s market cap?
Alcon’s market cap is $34.88B.
When is Alcon’s upcoming earnings report date?
Alcon’s upcoming earnings report date is Aug 10, 2026 which is in 18 days.
How were Alcon’s earnings last quarter?
Alcon released its earnings results on May 05, 2026. The company reported $0.814 earnings per share for the quarter, beating the consensus estimate of $0.782 by $0.032.
Is Alcon overvalued?
According to Wall Street analysts Alcon’s price is currently Undervalued.
Does Alcon pay dividends?
Alcon pays a Annually dividend of $0.359 which represents an annual dividend yield of 0.53%. See more information on Alcon dividends here
What is Alcon’s EPS estimate?
Alcon’s EPS estimate is 0.74.
How many shares outstanding does Alcon have?
Alcon has 499,700,000 shares outstanding.
What happened to Alcon’s price movement after its last earnings report?
Alcon reported an EPS of $0.814 in its last earnings report, beating expectations of $0.782. Following the earnings report the stock price went down -11.717%.
Which hedge fund is a major shareholder of Alcon?
Currently, no hedge funds are holding shares in ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$86.93 (6.89% Upside)
$86.93 (6.89% Upside)
Blogger Sentiment
Bullish
ALC Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 251.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.35%
12-Months-Change
Fundamentals
Return on Equity
0.53%
Trailing 12-Months
Asset Growth
1.97%
Trailing 12-Months
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
ALC Stock 12 Month Forecast
Average Price Target
$86.93
▲(6.89% Upside)
Technical Analysis
Ownership Overview
―
Insiders
12.32% Mutual Funds
0.34% Other Institutional Investors
70.43% Public Companies and
Individual Investors